{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.29","upperLimit":"37.1","value":"13"},{"groupId":"OG001","lowerLimit":"1.71","upperLimit":"21.9","value":"11.7"},{"groupId":"OG002","lowerLimit":"5","upperLimit":"20.6","value":"11.7"},{"groupId":"OG003","lowerLimit":"3.57","upperLimit":"45","value":"13.2"},{"groupId":"OG004","lowerLimit":"5.86","upperLimit":"18.1","value":"6.57"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"29"}],"units":"Participants"}],"description":"The distribution will be estimated by the methods of Kaplan and Meier. The estimates of PFS at specific time points will be calculated (eg, median, 1 year PFS).","dispersionType":"95% Confidence Interval","groups":[{"description":"Liposarcoma patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Cohort 1"},{"description":"Leiomyosarcoma patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Cohort 2"},{"description":"Undifferentiated Sarcoma patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"OG002","title":"Cohort 3"},{"description":"Malignant Peripheral Nerve Sheath Tumor patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"OG003","title":"Cohort 4"},{"description":"Other Sarcoma patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"OG004","title":"Cohort 5"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"The time between registration to disease progression or death, assessed up to 18 months","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Weeks"}